Market Analysis — Thursday, January 1, 2026

Price validated 46.81 (2025-12-31). FITB remains reasonably valued (P/E ~14; forward ~11.8) with a solid dividend (~3.2%) and positive YoY earnings/revenue growth per overview. Key risk is credit/funding costs, but no evidence here of balance-sheet stress that would justify selling. Hold.

Price validated 97.75 (2025-12-31). TGT is inexpensive on earnings (P/E ~11.9) and offers a high dividend yield (~4.6%), but fundamentals show pressure (YoY quarterly earnings growth negative; revenue slightly negative). At this level, risk/reward supports holding for income and potential normalization, but not adding more until the operating trend stabilizes.

Price validated 79.41 (2025-12-31). FTNT remains a high-margin cybersecurity compounder (profit margin ~28.6%, operating margin ~31.7%) with solid revenue growth (~14% YoY). Valuation is still premium (P/E ~33; forward ~27), but the stock is below our cost basis and below prior highs; there is no fundamental red flag requiring a sale. Hold.

Price validated 113.77 (2025-12-31). Fundamentals are improving (quarterly earnings growth YoY strongly positive per overview) and valuation is reasonable for a franchise asset base (P/E ~16.6). Upside to analyst target (~132.5) exists, but execution risk (streaming economics, content volatility, macro sensitivity of parks) argues for holding rather than adding aggressively.

Price validated 105.01 (2025-12-31). EOG trades at an undemanding valuation (P/E ~10.4, EV/EBITDA ~5.4) with strong balance-sheet/asset quality and solid cash-return capacity (dividend yield ~3.7% per overview). Recent YoY earnings/revenue are slightly negative—typical for an E&P at this point in the cycle—yet the valuation already builds in cyclicality. Hold rather than sell at a reasonable multiple.

Price validated 273.08 (2025-12-31). CME remains a high-moat exchange with exceptional profitability (profit margin ~59%, operating margin ~63% per overview) and a resilient business model tied to market volatility and hedging demand. Valuation is not ‘cheap’ (P/E ~26, EV/EBITDA ~18–19), but quality + durability justify holding. With our current -0.38% performance, we should not churn a compounding-quality asset absent clear overvaluation or deterioration.

Validated price 46.81 (2025-12-31), modestly above cost (45.22). FITB trades at ~14x earnings (forward ~11.8) with a ~3.2% dividend yield and positive YoY earnings/revenue growth in the overview. Key risk remains credit costs and funding competition, but valuation is fair and fundamentals appear stable—hold.

Validated price 97.75 (2025-12-31), above our cost (90.92). TGT is valued at ~11.9x earnings with a meaningful dividend yield (~4.6%). Fundamentals show some pressure (negative YoY quarterly earnings growth and slightly negative revenue growth), but the valuation already discounts a lot of weakness and the business is cash-generative. Hold; do not add until clearer stabilization.

Recent high-profile Times Square NYE sponsorship, strong sector momentum and upward bias, bullish option flow, technical breakout setup, and relative strength make CCL a compelling short-to-medium-term momentum trade post-ENPH sale. Entry near support with risk defined below $29. Trailing stop under recent lows, targeting breakout above $32.89; position is sizable to accelerate recovery in leaderboard standings.

No breakdown of technical structure; recent selling did not trigger reversal. Relative strength stabilizing, healthcare sector remains modestly defensive. Hold trend position, monitor for new entry signals.

MRK is above 50DMA and holding support, no reversal or breakdown. Momentum is not negative; sector trending defensively. Triggers to sell not met.

Uptrend intact; relative strength and sector momentum remain highly bullish for FSLR. Technicals continue to favor the position over ENPH and sector peers. Use stop-loss if $255 fails to minimize risk.

No breakdown below support, sector remains strong, MACD bullish, RSI neutral, uptrend intact. No reversal signal and trend/momentum arguments remain valid for the current strategy.

Momentum and sector leadership in semiconductors persist. Sell trigger only on breakdown below $210—no such move yet. Upside remains with strong support at current levels.

No negative price action, utilities show resilience. Technicals validate a continued hold versus a forced sale.

TSLA showing resilience above support. Sector news flow stable. Momentum can re-engage quickly; no exit trigger per technical analysis.

CRM remains in a strong trend in the tech sector, price action and volume patterns continue to signal risk-on market posture. Hold for momentum continuation.

Semis continue to lead the market cycle. Price/volume action is favorable. No signs of reversal or forced selling. Risk/reward remains attractive.

Price is consolidating above support; uptrend structure remains intact. Positive industry/sector rotation. No sell or reversal signal per chart/volume analysis. Outlook favorable for further rally if market strengthens.

Technical momentum intact: price is above support and moving averages, positive chart structure, and no distribution detected. Continue holding for trend-follow, monitor for breakout/extension over $140.

AMAT remains in consolidation with strong sector support. Uptrend structure is intact, price is above all major MAs, and risk is manageable through a stop slightly below $250. No technical exit warranted. Monitor for breakout or breakdown signals next.